Oxibendazole is an anthelmintics drug which is used to protect against roundworms, strongyles, threadworms, pinworms and lungworm infestations in horses and other domestic pets. Oxibendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules.

Fenbendazole (FBZ) is a broad-spectrum benzimidazole antiparasitic drug currently approved for use in numerous animal species, including rodents. Although nematodes, and in particular pinworms, are the main endoparasites of concern in laboratory rodents, FBZ also is indicated for use in other animal species against a wide spectrum of nematodes, tapeworms, flukes, and protozoa (Giardia duodenalis, Encephalitozoon intestinalis). The molecular mode of fenbendazole action consists in
binding of beta-tubulin monomer prior to dimerisation with alfa-tubulin which blocks subsequent microtubule formation. These microtubules are important organelles involved in the motility, the division and the secretion processes of cells in all living organisms. In the worms the blocking of microtubules perturbs the uptake of glucose, which eventually empties the glycogen reserves. This blocks the whole energy management mechanism of the worms that are paralyzed and die or are expelled. FBZ have a greater binding to nematode as compared to mammalian tubulin at 37°C. The oral LD50 of p-OH fenbendazole was >10 000 mg/kg b.w. in mice and rats.

Toltrazuril (Baycox, Procox, Tolcox, Toltrazuril) is a veterinary drug approved in Europe for the treatment of parasitic infections caused by roundworms and coccidia. In dogs it is used in combination with emodepside (Procox).

Nitroscanate (trade name Lopatol) is a medium-spectrum anthelmintic used on dogs and cats. It is available in the form of tablets for oral administration. It is not used on livestock. Nitroscanate is effective against the major gastrointestinal roundworms (nematodes) of dogs and cats (e.g.Toxocara canis, Toxocara cati, Ancylostoma spp, Uncinaria stenocephala) and tapeworms (e.g. Dipylidium caninum, Echinococcus granulosus, Taenia spp, etc.). The molecular mode of action of nitroscanate has not been elucidated. It is assumed that it acts as an uncoupler of the oxidative phosphorylation in the cell mitochondria, which disturbs the production of ATP, the cellular "fuel". This impairs the parasites motility and probably other processes as well.

Dichlorvos is a synthetic organic chemical used as an insecticide. Dichlorvos does not occur naturally in the environment, but is manufactured by industry. Dichlorvos is sold under many trade names including Vapona®, Atgard®, Nuvan®, and Task®. It is also used as an insecticide for slow release on pest-strips for pest control in homes.  Dichlorvos is used as an anthelmintic (worming agent) for dogs, swine, and horses, as a botacide (agent that kills fly larvae) for horses, and in flea collars for dogs. In 1995, EPA proposed cancellation of dichlorvos for all home uses, and for many commercial and industrial uses.

Cambendazole is a veterinary anti-parasitic drug, which was approved by FDA for the treatment of worm infections in horses. The mode of action of cambendazole is the inhibition of glucose uptake, fumarate reductase and phosphoenolpyruvate carboxykinase. Due to its mechanism of action, cambendazole causes the paralysis of parasites.

Monepantel (trade name Zolvix) is a new oral anthelmintic drug from a group of amino-acetonitrile derivatives with broad-spectrum activity against gastrointestinal nematodes of sheep, including adults and L4 larvae of the most important species. Monepantel have a novel mode of action involving a unique, nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunit ACR-23. Monepantel acts as a positive allosteric modulator of this receptor subunit, which is forced to open on stimulus but cannot close again, resulting in a constant uncontrolled flux of ions and finally in a depolarization of muscle cells leading to paralysis, spasmodic contractions of the anterior portion of the pharynx and ultimately death of adult nematodes. Monepantel-exposed C. elegans also exhibited molting defects and large vacuoles, characteristic for necrosis, are developed. Some nematode species lack ACR-23/MPTL-1 and predicted them to be Monepantel insensitive. Caenorhabditis nematodes equipped with ACR-23/MPTL-1 receptor subunits were found susceptible to Monepantel, whereas Pristionchus pacificus, closely related to these worms but lacking an ACR-23/MPTL-1 homolog, was tolerant. Monepantel shows an excellent tolerability in mammals and it is also active against multidrug-resistant parasites, indicating that its molecular target is absent or inaccessible in the host and is different from those of the classic anthelmintics. Safety pharmacological studies in rats indicate that MOP does not exert negative effects at a dose of 2000 mg/kg. Unfortunately, recent studies from New Zealand and Australia have reported that the efficacy of this new anthelmintic has declined markedly. Lack of efficacy of MOP was confirmed in the slaughtered sheep in which burdens of T. circumcincta and T. colubriformis showed no significant reductions. Whilst these two parasites now appear solidly resistant, the status of O. venulosum remains less clear.

Trichlorfon (Metrifonate), the organophosphorous cholinesterase inhibitor, O,O-dimethylhydroxy-2,2,2-trichlorethyl-phosphonate, has been used sporadically in the treatment of human schistosomiasis for a decade. It has selective and variable schistosomicidal activity against S. haematobium that results from its partial metabolism to a highly active anti-cholinesterase, dichlorvos. Schistosomal cholinesterase is more susceptible to this metabolite than that of the human host, but transient reductions in both plasma and erythrocyte cholinesterase activity are demonstrable at therapeutic dosage. However, despite early concerns about its potential toxicity, metrifonate is well tolerated and has been used effectively and extensively in large-scale control programmes. Its potential to enhance central nervous system cholinergic neurotransmission led to clinical trials for the treatment of people with Alzheimer's disease (AD).

Tetramisole is a racemic mixture of levamisole and its enantiomer dexamisole, which is a specific inhibitor of tissue non-specific alkaline phosphatase (TNAP). This drug is used in veterinary to treat of ascariasis and other worm infections e.g hook-"ms. And also is used as an immunostimulant (in that case it is used for longer periods of time).

Oxantel is a narrow-spectrum anthelmintic effective against whipworms in dogs and cats. It is ineffective against other roundworms, flukes, tapeworms or external parasites. Oxantel acts on the nervous system of the worms as inhibitors of acetylcholinesterase. Oxantel, a cholinergic anthelmintic and fumarate reductase inhibitor, significantly inhibited biofilm formation by P. gingivalis and disrupted established biofilms at concentrations below its MIC against planktonic cells. Oxantel was more effective against P. gingivalis in biofilm than metronidazole, a commonly used antibiotic for periodontitis. When oxantel was administrated to human beings for the treatment of trichuriasis, no drug reaction or side effects were reported, and the results of hematologic, biochemical and urinary examinations didn’t reveal any significant drug-related changes.